WITHDRAWN: Effects of cannabinoid antagonists on intake of different foods

Appetite ◽  
2006 ◽  
Author(s):  
C. Brown ◽  
J.D. Salamone ◽  
K. Sink ◽  
P.J. McLaughlin
ChemInform ◽  
2010 ◽  
Vol 30 (45) ◽  
pp. no-no
Author(s):  
Francis Barth ◽  
Murielle Rinaldi-Carmona

Life Sciences ◽  
2013 ◽  
Vol 93 (5-6) ◽  
pp. 187-193 ◽  
Author(s):  
Dana E. Selley ◽  
Sandra P. Welch ◽  
Laura J. Sim-Selley

2009 ◽  
Vol 161 (5) ◽  
pp. 655-662 ◽  
Author(s):  
Helen Butler ◽  
Márta Korbonits

The endocannabinoid system has emerged as a significant player in the control of energy balance and metabolism, through its direct central and peripheral effects, as well as via its interaction with other appetite-regulating pathways. There is mounting evidence that the endocannabinoid system is overactive in obesity and were it possible to safely dampen-down the elevated endocannabinoid tone, lipid and carbohydrate profiles could be improved and weight loss induced. The series of randomised clinical trials showed reproducible beneficial effects on weight, HbA1c and lipid parameters, in addition to other cardiovascular risk factors. However, to date, clinical developments have been halted because of psychiatric side effects. Although recent evidence has highlighted the importance of an appetite-independent, peripheral mode of action, it is still unclear whether selectively blocking the peripheral system could potentially solve the problem of the central side effects, which thus far has led to the demise of the cannabinoid antagonists as useful pharmaceuticals. In this concise review, we summarise the data on the metabolic effects of the cannabinoid pathway and its antagonists.


2001 ◽  
Vol 58 (4) ◽  
pp. 330 ◽  
Author(s):  
Deepak C. D'Souza ◽  
Thomas R. Kosten

Sign in / Sign up

Export Citation Format

Share Document